Feng Ye
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)University of Alberta(CA)Peking University(CN)Sichuan University(CN)China-Japan Friendship Hospital(CN)Shaoguan University(CN)First Affiliated Hospital of Xiamen University(CN)West China Hospital of Sichuan University(CN)Peking University Cancer Hospital(CN)Health and Family Planning Commission of Sichuan Province(CN)Xinjiang Academy of Agricultural and Reclamation Science(CN)Shaoguan Railway Hospital(CN)First People's Hospital of Nanning(CN)State Key Laboratory of Respiratory Disease(CN)Yangzhou University(CN)Guangzhou Medical University(CN)
Publications by Year
Research Areas
Cytokine Signaling Pathways and Interactions, Cancer-related molecular mechanisms research, Circular RNAs in diseases, interferon and immune responses, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China(2020)690 cited
- → Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis(2020)649 cited
- → Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial(2023)554 cited
- → circFBXW7 Inhibits Malignant Progression by Sponging miR-197-3p and Encoding a 185-aa Protein in Triple-Negative Breast Cancer(2019)259 cited
- → Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial(2022)232 cited